Penpulimab
- Generic Name
- Penpulimab
- Drug Type
- Biotech
- CAS Number
- 2350298-92-7
- Unique Ingredient Identifier
- IBS1BZ4E4I
- Indication
适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤成人患者。
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05975645
- Locations
- 🇨🇳
Affiliated hospital of zunyi medical university, Zunyi, Guizhou, China
🇨🇳Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳The First People's Hospital of Shangqiu City, Shangqiu, Henan, China
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
- Conditions
- Paraganglioma, MalignantPheochromocytoma MalignantPheochromocytoma, Metastatic
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT05885399
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: TQB2618 injection, Penpulimab injection, Paclitaxel, CisplatinDrug: TQB2618 injection, Penpulimab injection, TQB3617capsules
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT05834543
- Locations
- 🇨🇳
Tongling People's Hospital, Tongling, Anhui, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳AnYang Tumor Hospital, Anyang, Henan, China
An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT05800080
- Locations
- 🇨🇳
The First Affiliated Hospital of Air Force Military Medical University, Xi'an, Shaanxi, China
R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2023-03-27
- Target Recruit Count
- 60
- Registration Number
- NCT05784987
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Recurrent Squamous Cell Carcinoma of the Head and NeckMetastatic Squamous Cell Carcinoma
- Interventions
- Drug: TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05783921
- Locations
- 🇨🇳
Gansu Prouincial Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Jiangmen Central Hospital, Jiangmen, Guangdong, China
Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05726175
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China
Penpulimab in Maintenance Therapy in Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- WEI XU
- Target Recruit Count
- 167
- Registration Number
- NCT05680038
SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
- Conditions
- Rectal CancerLocally Advanced
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT05576480
TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride InjectionDrug: TQB2618 injection; Penpulimab injection
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05563480
- Locations
- 🇨🇳
The Fifth Affiliated Hospital Sun Yat sen University, Zhuhai, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.